No Data
BioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of Its Oral Drug Piclidenoson With FDA & EMA-Approved Protocol
XCan-Fite Partner Vetbiolix Accelerate Piclidenoson Development With Clinical Trial For Canine Osteoarthritis
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development With Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
12 Health Care Stocks Moving In Wednesday's Intraday Session
Can-Fite Biopharma Shares Are Trading Lower. The Company Announced a Phase II Design Is Completed and Preparatory Work Is Undergoing for the Initiation of Clinical Study in the Rare Genetic Disease Lowe Syndrome.
Unlock the Full List
Maddtrinity : I'm hopeful but it's not until tomorrow T.T still though, looking forward to it. I was hopeful they'd have an annual report they were gonna release either yesterday or today as well but it doesn't look like it
Trytosaveabit OP Maddtrinity : Right! But that means lotsa eyes over weekend. And that may bring some attention to the tickers from people who may not even know they exist? Hehehe GL
Maddtrinity Trytosaveabit OP : GL to you as well. I wonder if that might be why they haven't released their annual report yet![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Trytosaveabit OP Maddtrinity : Not sure when its out? Thank you